The global push to develop coronavirus vaccines is accelerating, with companies in China, Europe and the U.S. reporting positive developments in trials of their shots.
A Moderna Inc. vaccine candidate produced antibodies in all participants in a study, and early tests of experimental shots from Pfizer Inc. and BioNtech SE, as well as a partnership of Oxford and AstraZeneca Plc, have also shown favorable immune responses in people and animals. CanSino Biologics has received authorization for a limited deployment of its shot among the Chinese military. The U.S. government is working with a number of pharmaceutical companies under its “Operation Warp Speed” program, with the aim of securing shots by the end of the year.